FLT3 appears to be a promising therapeutic target, in light of its upregulation in several forms of acute leukemia, and a deeper understanding of FLT3 mutations through valid experimental models could improve the development of more effective FLT3 inhibitors in overcoming DR. This evidence concerns the gene FLT3 and acute leukemia.